Health Canada Greenlights Kashiv’s Pegfilgrastim Biosimilar

The Drug Will Be Sold As Pexegra By Local Partner JAMP Pharma

After receiving an approval for the Neulasta rival in the US in May 2022, Kashiv BioSciences has now added a further North American country with a positive nod from Canada’s health agency.

Red pin on Canada on the map
Denosumab key patents will expire in 2025 • Source: Shutterstock

More from Biosimilars

More from Generics Bulletin